Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform

▴ Calla Lily Clinical Care and Merck
Strategic collaboration supporting the continued development of a novel intravaginal drug delivery approach to address unmet needs in women’s health

London, UK, 10 February 2026: Calla Lily Clinical Care, a women’s health-focused medical technology company, and Merck, a leading science and technology company, have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. The collaboration represents the first industry partnership for the Callavid technology.

Callavid is a transformational leak-resistant medical device designed to address challenges associated with the self-administration of vaginal therapeutics. Administration via the vaginal route can be associated with increased patient anxiety related to positioning, dosing accuracy, and concerns around leakage, particularly for certain therapeutics used in fertility treatments, oncology, and hormone therapies.

Developed by the team at Calla Lily Clinical Care, Callavid’s patented leak-free design delivers vaginal therapeutics using a small, tampon-shaped device combined with an integrated absorbent liner. Callavid is designed for hygienic insertion, remains in place during drug absorption, and can be easily and cleanly removed. By supporting more consistent drug delivery and reducing concerns around leakage and positioning, Callavid is uniquely designed to improve the overall patient experience when administering vaginal medications.

 

Thang Vo-Ta, Co-founder and CEO of Calla Lily Clinical Care, commented: “This collaboration with Merck marks an important milestone in the development of Callavid, our novel vaginal drug delivery platform. Merck’s scientific heritage and forward-looking approach to innovation make them an ideal partner as we work to address long-standing unmet needs in women’s health. By improving how vaginal therapeutics are delivered and experienced, Callavid has the potential to enhance both patient outcomes and quality of life. We see this collaboration as a meaningful step toward translating our technology into real-world clinical and patient impact.”

 

Dr Lara Zibners, Co-founder and Chairman of Calla Lily Clinical Care, said: “Our initial engagement with Merck through the Merck Innovation Challenge in October 2024 was an important moment of alignment around the need for more patient-centric innovation in women’s health. As both a clinician and a patient, I have seen how profoundly drug delivery can shape treatment experience. This collaboration builds on that early dialogue and reflects a shared interest in rigorously exploring new approaches that may improve how therapies are delivered and experienced by patients.”

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026